ClinicalTrials.gg
TerminatedNCT00920582Updated Dec 20, 2023Results posted

Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus

A Phase 3 interventional study of Teplizumab Herold Regimen and Placebo in Type 1 Diabetes Mellitus, sponsored by MacroGenics. Terminated at 118 sites in 16 countries. Open to participants aged 8 Years to 35 Years. Per ClinicalTrials.gov, last updated 2023-12-20.

Sponsored by MacroGenics · Phase 3, Interventional, and Treatment

Why this study was terminated
Business decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
254
Allocation
Randomized
Ages
8 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing teplizumab in Diabetes Mellitus, Type 1 — 2 open to participants now, 3 under way, 1 of them phase 3. teplizumab · Diabetes Mellitus, Type 1.

Enrollment
4th of 11
254 · median 60
Started
2009
the only one that year
Phase 3
3 of 11
1 open now
Registered
3rd of 11
by date
Lead sponsor
2 of 11
MacroGenics

Among the 11 studies testing teplizumab in Diabetes Mellitus, Type 1, this one is the 4th largest by enrollment, is the only one that started in 2009, is one of 3 in phase 3, and was the 3rd registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

2 of the 11 studies testing teplizumab in Diabetes Mellitus, Type 1 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About teplizumab

teplizumab: first FDA approval 2022 (TZIELD), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 8 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing teplizumab in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

The primary purpose of this study is to determine whether teplizumab (MGA031) infusions lead to greater reductions in insulin requirements in conjunction with near normal blood sugar control compared to placebo in patients recently diagnosed with type 1 diabetes.

03

Conditions studied

  • Type 1 Diabetes Mellitus
04

Who can participate

Ages eligible
8 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects 8-35 years old
  2. Body weight > 36 Kg
  3. Diagnosis of diabetes mellitus according to the American Diabetes Association (ADA) criteria
  4. Randomization on Study Day 0 within 12 weeks of first visit to any physician for symptoms or signs of diabetes
  5. Requires insulin for T1DM or has required insulin at some time between diagnosis and administration of study drug
  6. Detectable fasting or stimulated C-peptide level (above the lower limit of the reportable range of the assay) at screening
  7. Diagnosis of T1DM as evidenced by one positive result on testing for any of the following antibodies at screening:

    • Islet-cell autoantibodies 512 (ICA512)/islet antigen-2 (IA-2),
    • Glutamic acid decarboxylase (GAD) autoantibodies, or
    • Insulin autoantibodies (in subjects on insulin for more than 2 weeks, ICA512/IA-2 or GAD must be positive).

Exclusion criteria

Exclusion Criteria:

  1. Prior administration of a monoclonal antibody-within the 1 year before randomization
  2. Participation in any type of therapeutic drug or vaccine clinical trial within the last 12 weeks before randomization at Study Day 0
  3. Any medical condition that, in the opinion of the investigator, would interfere with safe completion of the trial
  4. Pregnant females or lactating females who intend to provide their own breast milk to the baby during the study
  5. Current therapy with GLP-1 receptor agonists (e.g., exenatide or pramlintide), or any other agents that might stimulate pancreatic beta cell regeneration or insulin secretion
  6. Current treatment with oral antidiabetic agents
  7. Evidence of active or latent tuberculosis
  8. Vaccination with a live virus or organism within the 8 weeks before randomization continuing through Week 52 of the study.

    • Influenza vaccination with a killed virus, including booster vaccinations, within 4 weeks before or after each dosing cycle.
    • Vaccination with other antigens or killed organisms within 8 weeks before or after each dosing cycle
  9. Any infectious mononucleosis-like illness within the 6 months before randomization
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
254 participants (actual)

Study arms

  • Experimental
    Herold Regimen

    14-day cycle of teplizumab consisting of daily IV doses of 51 µg/m2, 103 µg/m2, 207 µg/m2, and 413 µg/m2 on Study Days 1-4, respectively, and one dose of 826 µg/m2 on each of Study Days 5-14. Repeat at Week 26

    Biological: Teplizumab Herold Regimen

  • Experimental
    33.3% Herold Regimen

    Subjects received a 14-day cycle of teplizumab consisting of daily IV doses of 17 µg/m2, 34 µg/m2, 68 µg/m2, and 136 µg/m2 on Study Days 1-4, respectively, and one dose of 273 µg/m2 on each of Study Days 5-14. Repeat at Week 26

    Biological: Teplizumab 33.3% Herold Regimen

  • Experimental
    Curtailed Herold Regimen

    Subjects received a 6 day cycle of teplizumab consisting of daily IV doses of 51 µg/m2, 103 µg/m2, 207 µg/m2, and 413 µg/m2 on Study Days 1-4, respectively, and one dose of 826 µg/m2 on each of Study Days 5-6, followed by 8 days of IV placebo (Study Days 7-14). Repeat at Week 26

    Biological: Teplizumab Curtailed Herold Regimen

  • Placebo comparator
    Placebo

    14-day cycle of placebo consisting of daily IV doses. Repeat at Week 26

    Drug: Placebo

Interventions

  • Full dose of teplizumab IV for 14 days, repeated at Week 26

    Also known as: MGA031

  • DrugPlacebo

    IV dosing daily for 14 days repeated at Week 26

  • One third full dose of teplizumab IV for 14 days, repeated at Week 26

    Also known as: MGA031

  • BiologicalTeplizumab Curtailed Herold Regimen

    Full dose of teplizumab IV for 6 days followed by placebo for 8 days, repeated at Week 26

06

What researchers measure

Primary outcomes

  1. Proportion of Subjects With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and Hemoglobin A1c (HbA1c) Level of Less Than 6.5%.

    Time frame: 52 weeks after randomization

  2. Mean Change From Baseline in HbA1c Between Teplizumab and Placebo

    Time frame: 52 weeks after randomization

Secondary outcomes

  1. The Change in Beta-cell Function as Measured by C-peptide Secretory Response Following a Mixed Meal

    Time frame: 52 weeks after randomization

  2. The Change in Beta-cell Function as Measured by C-peptide Secretory Response Following a Mixed Meal

    Time frame: 104 weeks after randomization

  3. Mean Number of Total, Major, Minor and Nocturnal Hypoglycemia Events

    Number of hypoglycemic events by type per participant

    Time frame: Throughout the study up to 2 years

  4. Mean Number of Daily Insulin Injections

    Time frame: 52 weeks after randomization

  5. Number of Subjects With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and Hemoglobin A1c (HbA1c) Level of Less Than 6.5%.

    Time frame: 104 weeks after randomization

  6. The Proportion of Subjects Who Have Both a Total Daily Insulin Dose < 0.5 U/Kg/Day and Hemoglobin A1c (HbA1c) Level < 7.0%

    Time frame: 52 weeks after randomization

  7. The Mean HbA1c Change From Baseline

    Time frame: 104 weeks after randomization

  8. Number of Participants With Adverse Events

    Time frame: throughout the study, up to 104 weeks

  9. Number of Participants With Serious Adverse Events

    Time frame: throughout the study, up to 104 weeks

07

Results

Posted Dec 20, 2023

Participant flow

Participant flow — Overall Study
MilestoneHerold Regimen33.3% Herold RegimenCurtailed Herold RegimenPlacebo
Started63666362
Completed50605257
Not completed136115
Withdrew: Lost to follow-up5120
Withdrew: Withdrawal by subject5463
Withdrew: Protocol violation1000
Withdrew: Other2132

Outcome measures

PrimaryProportion of Subjects With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and Hemoglobin A1c (HbA1c) Level of Less Than 6.5%.
Time frame:
52 weeks after randomization
Reported as:
Count of participants · Participants
Proportion of Subjects With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and Hemoglobin A1c (HbA1c) Level of Less Than 6.5%.
ParticipantsHerold Regimen33.3% Herold RegimenCurtailed Herold RegimenPlacebo
Proportion of Subjects With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and Hemoglobin A1c (HbA1c) Level of Less Than 6.5%.8896
Statistical analysis
  • Herold Regimen vs Placebo · Mantel Haenszel · p = 0.609 · Odds ratio (or): 1.348 · 95% CI 0.431 to 4.219
  • 33.3% Herold Regimen vs Placebo · Mantel Haenszel · p = 0.601 · Odds ratio (or): 1.356 · 95% CI 0.453 to 4.230
  • Curtailed Herold Regimen vs Placebo · Mantel Haenszel · p = 0.400 · Odds ratio (or): 1.624 · 95% CI 0.521 to 5.066
PrimaryMean Change From Baseline in HbA1c Between Teplizumab and Placebo
Time frame:
52 weeks after randomization
Reported as:
Mean · percent HbA1c
Mean Change From Baseline in HbA1c Between Teplizumab and Placebo
percent HbA1cHerold Regimen33.3% Herold RegimenCurtailed Herold RegimenPlacebo
Mean Change From Baseline in HbA1c Between Teplizumab and Placebo0.01 ± 1.803-0.02 ± 2.1690.35 ± 25.120.03 ± 2.566
SecondaryThe Change in Beta-cell Function as Measured by C-peptide Secretory Response Following a Mixed Meal
Time frame:
52 weeks after randomization
Reported as:
Mean · nmol/L
The Change in Beta-cell Function as Measured by C-peptide Secretory Response Following a Mixed Meal
nmol/LHerold Regimen33.3% Herold RegimenCurtailed Herold RegimenPlacebo
The Change in Beta-cell Function as Measured by C-peptide Secretory Response Following a Mixed Meal0.04 ± 0.276-0.05 ± 0.4560.04 ± 0.287-0.04 ± 0.419
Statistical analysis
  • Herold Regimen vs Placebo · ANCOVA · p = 0.365 · Mean difference (final values): -0.028 · 95% CI -0.086 to 0.031
  • 33.3% Herold Regimen vs Placebo · ANCOVA · p = 0.842 · Mean difference (final values): -0.007 · 95% CI -0.078 to 0.064
  • Curtailed Herold Regimen vs Placebo · ANCOVA · p = 0.565 · Mean difference (final values): 0.021 · 95% CI -0.089 to 0.171
SecondaryThe Change in Beta-cell Function as Measured by C-peptide Secretory Response Following a Mixed Meal
Time frame:
104 weeks after randomization

No measurements were reported for this outcome.

SecondaryMean Number of Total, Major, Minor and Nocturnal Hypoglycemia Events

Number of hypoglycemic events by type per participant

Time frame:
Throughout the study up to 2 years
Reported as:
Mean · events
Mean Number of Total, Major, Minor and Nocturnal Hypoglycemia Events
eventsHerold Regimen33.3% Herold RegimenCurtailed Herold RegimenPlacebo
Total (any)13.7 ± 22.3515.9 ± 22.9018.9 ± 41.4215.5 ± 22.70
Minor hypoglycemia4.1 ± 6.974.4 ± 6.385.4 ± 12.114.7 ± 10.45
Major hypoglycemia10.0 ± 0.130.1 ± 0.420.0 ± 0.180.0 ± 0.13
Nocturnal hypoglycemia2.0 ± 3.172.1 ± 5.541.4 ± 2.461.6 ± 3.33
SecondaryMean Number of Daily Insulin Injections
Time frame:
52 weeks after randomization

No measurements were reported for this outcome.

SecondaryNumber of Subjects With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and Hemoglobin A1c (HbA1c) Level of Less Than 6.5%.
Time frame:
104 weeks after randomization
Reported as:
Count of participants · Participants
Number of Subjects With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and Hemoglobin A1c (HbA1c) Level of Less Than 6.5%.
ParticipantsHerold Regimen33.3% Herold RegimenCurtailed Herold RegimenPlacebo
Number of Subjects With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and Hemoglobin A1c (HbA1c) Level of Less Than 6.5%.1211
SecondaryThe Proportion of Subjects Who Have Both a Total Daily Insulin Dose < 0.5 U/Kg/Day and Hemoglobin A1c (HbA1c) Level < 7.0%
Time frame:
52 weeks after randomization
Reported as:
Count of participants · Participants
The Proportion of Subjects Who Have Both a Total Daily Insulin Dose < 0.5 U/Kg/Day and Hemoglobin A1c (HbA1c) Level < 7.0%
ParticipantsHerold Regimen33.3% Herold RegimenCurtailed Herold RegimenPlacebo
The Proportion of Subjects Who Have Both a Total Daily Insulin Dose < 0.5 U/Kg/Day and Hemoglobin A1c (HbA1c) Level < 7.0%1310127
Statistical analysis
  • Herold Regimen vs Placebo · Mantel Haenszel · p = 0.142 · Odds ratio (or): 2.197 · 95% CI 0.764 to 6.312
  • 33.3% Herold Regimen vs Placebo · Mantel Haenszel · p = 0.460 · Odds ratio (or): 1.487 · 95% CI 0.517 to 4.278
  • Curtailed Herold Regimen vs Placebo · Mantel Haenszel · p = 0.199 · Odds ratio (or): 1.954 · 95% CI 0.690 to 5.532
SecondaryThe Mean HbA1c Change From Baseline
Time frame:
104 weeks after randomization
Reported as:
Mean · percent glycosylated hemoglobin
The Mean HbA1c Change From Baseline
percent glycosylated hemoglobinHerold Regimen33.3% Herold RegimenCurtailed Herold RegimenPlacebo
The Mean HbA1c Change From Baseline1.05 ± 2.3441.11 ± 2.4940.71 ± 3.7401.21 ± 2.857
SecondaryNumber of Participants With Adverse Events
Time frame:
throughout the study, up to 104 weeks
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsHerold Regimen33.3% Herold RegimenCurtailed Herold RegimenPlacebo
Number of Participants With Adverse Events63666362
SecondaryNumber of Participants With Serious Adverse Events
Time frame:
throughout the study, up to 104 weeks
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events
ParticipantsHerold Regimen33.3% Herold RegimenCurtailed Herold RegimenPlacebo
Number of Participants With Serious Adverse Events7683

Adverse events

Collected over Throughout the study, up to 2 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Herold Regimen0/63 (0%)7/63 (11.1%)63/63 (100%)
33.3% Herold Regimen0/66 (0%)6/66 (9.1%)66/66 (100%)
Curtailed Herold Regimen0/63 (0%)8/63 (12.7%)63/63 (100%)
Placebo0/62 (0%)3/62 (4.8%)62/62 (100%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventHerold Regimen33.3% Herold RegimenCurtailed Herold RegimenPlacebo
Diabetic ketoacidosisMetabolism and nutrition disorders1/631/663/630/62
HyperglycaemiaMetabolism and nutrition disorders1/630/660/632/62
Hypoglycaemic seizureMetabolism and nutrition disorders0/631/662/630/62
GastroenteritisInfections and infestations0/630/660/631/62
LymphopeniaBlood and lymphatic system disorders1/630/661/630/62
Abdominal painGastrointestinal disorders1/630/660/630/62
GastritisGastrointestinal disorders0/630/661/630/62
Cytokine release syndromeImmune system disorders1/631/660/630/62
Hepatic amoebiasisInfections and infestations0/630/661/630/62
PyelonephritisInfections and infestations1/630/660/630/62
Most frequent other events
Showing 10 of 62
Most frequent other events
EventHerold Regimen33.3% Herold RegimenCurtailed Herold RegimenPlacebo
White blood cell count decreasedInvestigations39/6328/6629/6313/62
Blood bicarbonate decreasedInvestigations31/6338/6627/6326/62
Lymphocyte count decreasedInvestigations35/6332/6633/636/62
LymphopeniaBlood and lymphatic system disorders26/6321/6625/636/62
Haemoglobin decreasedInvestigations23/6320/6622/6317/62
Neutrophil count decreasedInvestigations23/6316/6623/6310/62
Aspartate aminotransferase increasedInvestigations20/6315/6622/6311/62
PyrexiaGeneral disorders14/6312/6620/637/62
Alanine aminotransferase increasedInvestigations20/6314/6619/636/62
Blood calcium decreasedInvestigations20/6313/668/6311/62

Baseline characteristics

Age, Continuous
Age, Continuous(years)Herold Regimen33.3% Herold RegimenCurtailed Herold RegimenPlaceboTotal
Median16.0 (8.0 to 23.0)16.0 (8.0 to 35.0)15.0 (8.0 to 33.0)16.0 (9.0 to 35.0)16.0 (8.0 to 35.0)
Age, Customized
Age, Customized(Participants)Herold Regimen33.3% Herold RegimenCurtailed Herold RegimenPlaceboTotal
8-11 years1312131149
12-17 years24292425102
18-35 years26252626103
Sex: Female, Male
Sex: Female, Male(Participants)Herold Regimen33.3% Herold RegimenCurtailed Herold RegimenPlaceboTotal
Female2520172183
Male38464641171
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Herold Regimen33.3% Herold RegimenCurtailed Herold RegimenPlaceboTotal
Hispanic or Latino01146
Not Hispanic or Latino63656258248
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Herold Regimen33.3% Herold RegimenCurtailed Herold RegimenPlaceboTotal
American Indian or Alaska Native00000
Asian2526252399
Native Hawaiian or Other Pacific Islander00000
Black or African American00325
White36393537147
More than one race00000
Unknown or Not Reported21003
Region of Enrollment
Region of Enrollment(participants)Herold Regimen33.3% Herold RegimenCurtailed Herold RegimenPlaceboTotal
Romania331310
United States1717171768
Czechia456520
Ukraine554620
United Kingdom00101
India2526252399
Spain12227
Belgium10001
Finland01001
Poland32229
Mexico00011
Israel334212
Germany12115
08

Study locations

118 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • NEA Clinic
    Jonesboro, Arkansas 72401, United States
  • Arkansas Children's Hospital
    Little Rock, Arkansas 72272, United States
  • Clinical Innovations Inc. Research Facility
    Costa Mesa, California 92626, United States
  • Axis Clinical Trials
    Los Angeles, California 90036, United States
  • Diabetes Associates Medical Group, Inc
    Orange, California 92868, United States
  • Clinical Innovations, Inc.
    Riverside, California 92506, United States
  • San Diego Clinical Trials
    San Diego, California 92120, United States
  • Ronald Chochinov Md Inc
    Ventura, California 93003, United States
  • Yale University
    New Haven, Connecticut 06519, United States
  • Christiana Care Research Institute
    Newark, Delaware 19713, United States
  • Richard Hays, MD
    Wellington, Florida 33414, United States
  • Atlanta Diabetes Associates
    Atlanta, Georgia 30309, United States
  • John H Stoger Jr. Hospital of Cook County, Cook County Hospital
    Chicago, Illinois 60612, United States
  • Indiana University School of Medicine
    Indianapolis, Indiana 46202, United States
  • University of Iowa Children's Hospital
    Iowa City, Iowa 52242-1083, United States
  • Mid-America Diabetes Associates
    Wichita, Kansas 67211, United States
  • St. Agnes Hospital
    Baltimore, Maryland 21229, United States
  • Maryland Diabetes & Endocrine Associates
    Rockville, Maryland 20852, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Alzohaili Medical Consultants
    Dearborn, Michigan 48126, United States
  • Children's Hospitals and Clinics of Minnesota
    Saint Paul, Minnesota 55102, United States
  • University of Missouri - Columbia, Cosmopolitan Diabetes and Endocrinology
    Columbia, Missouri 65212, United States
  • The Children's Mercy Hospital
    Kansas City, Missouri 64108, United States
  • Saint Barnabas Medical Center
    Livingston, New Jersey 07039, United States
  • Albany Medical College
    Albany, New York 12208, United States
  • Bassett Healthcare
    Cooperstown, New York 13326, United States
  • East Carolina University, Brody School of Medicine
    Greenville, North Carolina 27834, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • GHS Pediatric Endocrinology
    Greenville, South Carolina 29615, United States
  • AM Diabetes & Endocrinology Center
    Bartlett, Tennessee 38133, United States
  • University Diabetes & Endocrine Consultants
    Chattanooga, Tennessee 37403, United States
  • LeBonheur Children's Medical Center
    Memphis, Tennessee 38103, United States
  • Research Institute of Dallas
    Dallas, Texas 75231, United States
  • Southwest Clinical Trials
    Houston, Texas 77074, United States
  • Houston Center for Clinical Research
    Houston, Texas 77081, United States
  • Medical & Surgical Clinic of Irving
    Irving, Texas 75061, United States
  • InVisions Consultants, LLC
    San Antonio, Texas 78217, United States
  • Diabetes and Glandular Disease Research Associates, PA
    San Antonio, Texas 78229, United States
  • Endocrine Research Specialists
    Ogden, Utah 84403, United States
  • Virginia Commonwealth University-Division of Pediatric Endocrinology & Metabolism
    Richmond, Virginia 23219, United States
  • University of Washington
    Seattle, Washington 98122, United States
  • Universitair Ziekenhuis Antwerpen
    Edegem, Antwerp 2650, Belgium
  • Cliniques du Sud Luxembourg - Vivalia
    Arlon, 6700, Belgium
  • I. Detska interni klinika,Fakultni nemocnice Brno Detska nemocnice
    Brno, 62500, Czechia
  • Klinika deti a dorostu FN Kralovske Vinohrady
    Praha, 10034, Czechia
  • Centrum diabetologie, Institut klinicke a experimentalni mediciny
    Praha, 14021, Czechia
  • Pediatricka klinika UK 2.LF a FN Motol, Fakultni nemocnice v Motole
    Praha, 15006, Czechia
  • Detska klinika, Masarykova nemocnice v Usti nad Labem, o.z.
    Usti nad Labem, 40113, Czechia
  • Kuopio University Hospital
    Kuopio, 70210, Finland
  • Central Hospital of Mikkeli
    Mikkeli, 50100, Finland
  • Oulu University Hospital
    Oulu, 90029, Finland
  • CHU de Besançon
    Besançon, 25030, France
  • CHU de Brest Hôpital de la Cavale Blanche
    Brest, 29609, France
  • Centre Hospitalier Sud Francilien
    Corbeil-Essonnes, 91106, France
  • CHU de Bordeaux
    Pessac, 33604, France
  • CHU de Reims
    Reims, 51092, France
  • Hôpitaux Universitaires de Strasbourg Hôpital Civil
    Strasbourg, 67091, France
  • Diabetes-Klinik Bad Nauheim GmbH
    Bad Nauheim, 61231, Germany
  • Herz und Diabeteszentrum Nordrhein-Westfallen
    Bad Oeynhausen, 32545, Germany
  • Charite, Campus Benjamin Franklin
    Berlin, 12200, Germany
  • Universitätsklinikum Düsseldorf
    Düsseldorf, 20225, Germany
  • Universitatsklinik Giessen
    Giessen, 35392, Germany
  • Asklepios Westklinikum Hamburg
    Hamburg, 22559, Germany
  • Kinderkrankenhaus auf der Bult
    Hannover, 30173, Germany
  • Universitatsklinikum Heidelberg
    Heidelberg, 69120, Germany
  • Medwin Hospitals
    Hyderabad, Andhra Pradesh 500001, India
  • King George Hospital
    Visakhapatnam, Andhra Pradesh 530002, India
  • Maulana Azad Medical College and Associated Hospitals
    New Delhi, Delhi 110002, India
  • DHL Research Centre
    Ahmedabad, Gujarat 380015, India
  • Bangalore Diabetes Centre
    Bangalore, Karnataka 560043, India
  • Health & Research Centre
    Trivandrum, Kerala 695011, India
  • Gandhi's Research Institute
    Nagpur, Maharashtra 440010, India
  • Grant Medical Foundation
    Pune, Maharashtra 411001, India
  • KEM Hospital Research Center
    Pune, Maharashtra 411011, India
  • Kalinga Hospital Limited
    Bhubaneswar, Orissa 751023, India
  • Diabetes-Thyroid-Hormone Research Institute Pvt. Ltd.
    Madhya, Pradesh 452001, India
  • Dayanand Medical College and Hospital
    Ludhiana, Punjab 141001, India
  • Fortis Escorts Hospital
    Jaipur, Rajasthan 302017, India
  • Hormone Care & Research Center
    Ghaziabad, Uttar Pradesh 201002, India
  • B. P. Poddar Hospital & Medical Research Limited
    Kolkata, West Bengal 700053, India
  • Apollo Glenagles Hospital
    Kolkata, West Bengal 700054, India
  • Hillel Yaffe Medical Center
    Hadera, 38100, Israel
  • Mayer Children's Hospital of Haifa
    Haifa, 31096, Israel
  • The E. Wolfson Medical Center
    Holon, 58100, Israel
  • Schneider Children's Medical
    Petach-Tikva, 49202, Israel
  • The Safra Children's Hospital, The Chaim Sheba Medical Center
    Ramat-Gan, 52621, Israel
  • Struttura Complessa di Pediatria, Azienda Ospedaliero-Universitaria di Modena,
    Modena, 41124, Italy
  • U.O. di Malattie del Metabolismo
    Pisa, 16132, Italy
  • U.O. di Malattie Metaboliche e Diabetologia
    Pisa, 56124, Italy
  • Hospital y Clinica OCA / Monterrey International Research Center
    Monterrey, Nuevo León 64000, Mexico
  • Medical Care & Research
    Merida, Yucatan 97070, Mexico
  • Centro Especializado en Diabetes, Obesidad y Prevención de Enfermedades Cardiovasculares, S.C.
    Mexico, Distrito Federal, 11650, Mexico
  • Stichting Diabeter
    Rotterdam, 3011 TG, Netherlands
  • Uniwersytecki Szpital Kliniczny w Bialymstoku
    Bialystok, 15-276, Poland
  • Uniwersyteckie Centrum Kliniczne
    Gdansk, 80-952, Poland
  • Wojewódzki Specjalistyczny Szpital Dzieciecy
    Kielce, 25-734, Poland
  • Samodzielny Publiczny Dzieciecy Szpital Kliniczny w Warszawie-Filia
    Warszawa, 01-184, Poland
  • Samodzielny Publiczny Szpital Kliniczny Nr1 we Wroclawiu
    Wroclaw, 50-376, Poland
  • Samodzielny Publiczny Zaklad Opieki Zdrowotnej Uniwersytecki Szpital Kliniczny Nr 4
    Łódź, 91-738, Poland

Showing the first 100 of 118 sites across 16 countries. Choose a country and city above to see the rest.

09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2009, a primary completion of Apr 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2023, 11 years 8 months after primary completion. A results delay was requested in Feb 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2009
First posted
Jun 15, 2009
Start
Sep 2009
Primary completionActual
Apr 2012
CompletionActual
Jul 2012
Results delay requested
Feb 28, 2013
Results first posted
Dec 20, 2023
Last update
Dec 20, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00920582
Lead sponsor
MacroGenics
Responsible party
Sponsor
First posted
Jun 15, 2009
Start date
Sep 2009
Primary completion
Apr 2012
Completion
Jul 2012
Results posted
Dec 20, 2023
Last update
Dec 20, 2023

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Teplizumab

Start the discussion